New schedules of interferon for chronic hepatitis C

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 227-231

  Davis, Gary L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic hepatitis C; HCV; Interferon schedules

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG COST; HEPATITIS C; HUMAN; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0033456196     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80407-3     Document Type: Conference Paper

References (46)

1. Davis GL, Baiart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant Interferon alpha. A multicenter randomized controlled study. N Engl J Med 1989: 321: 15011506.
2. Di BisceglieAM, Martin P, Kassianides C et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized double-blind, placebo-controlled trial. N Engl J Med 1989: 321: 1506-1510.
3. TinE F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomized clinical trials. J Hepatol 1991: 13: 192-199.
4. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996: 24: 778-789.
5. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alpha2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998: 339: 1485-1492.
6. Poynard T, Bedossa P, Chevallier M et al. A comparison of three interferon alpha-2b regimens for the long term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995: 332: 14571462.
7. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alpha-2b for chronic hepatitis C effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. J Hepatol 1995: 23: 487-496.
8. Carithers RL, Emerson S. Therapy of hepatitis C: Meta-analysis of interferon alpha-2b trials. Hepatology 1997: 26(Suppl): 83-88.
9. Patterson JL, Fernandez-Larson R. Molecular action of ribavirin. Rev Infect Dis 1990: 12: 1132-1146.
10. Dusheiko G, Main J, Thomas H et al. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study. J Hepatol 1996: 25: 591-598.
11. Di Bisceglie AM, Shindo M, Hong T-L et al. Pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992: 16: 649654.
12. Bodenheimer HC, Lindsay KL, Davis GL et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997: 26: 473-477.
13. Reichard O, Norkrans G, Fryden A et al. Alpha-interferon and ribavirin versus alpha-interferon alone as therapy for chronic hepatitis C - a randomized, double-blind, placebo-controlled study. Lancet 1998: 351: 83-87.
14. Chemello L, Cavaletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of Interferon alpha and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995: 23(Suppl): 8-12.
15. Mètreau JM, Calmus Y, Poupon R et al. Twelve-month treatment compared to 6-month treament does not improve the efficacy of alpha-interferon in NANB chronic active hepatitis (abstract). Hepatology 1991: 14: 72A.
16. Jouet P, Roudot-Thoraval F, Dhumeaux D et al. Comparative efficacy of interferon alpha in cirrhotic and noncirrhotic patients with non-A, non-B C hepatitis. Gastroenterology 1994: 106: 686.
17. Benhamou JP, Hopf U, Rizzetto M et al. Long-term lymphoblastoid interferon enhances sustained responses and improves histological activity up to 12 months post-treatment (abstract). Hepatology 1995: 22: 151 A.
18. Lin R, Roach E, Zimmerman M, Strasser.S, Parrel G. Interferon alpha-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol 1995:23:487496.
19. Lindsay KL, Davis GL, Schiff ER et al. Response to higher doses of interferon alpha-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1996: 24: 1034-1040.
20. Di Marco V, Lo lacono O, Camma C, Almasio PPL, Vaccaro A, Fuschi P et al. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. J Med Virol 1997: 51: 17-24.
21. Tassopoulos NC, Karvountis G, Touloumi G, Delladetsima JK, Paptheodoridis GV, Katsoulidou A et al. Comparative efficacy of high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. Am J Gastroenterol 1996: 91: 1734-1738.
22. Alberti A, Chemello L, Bonetti P, Casarin C, Diodati G, Cavalletto L et al. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. J Hepatol 1993: 17(Suppl 3): S123-126.
23. Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamura K. A controlled study to determine the optimal dose regimen of interferon alpha-2b in chronic hepatitis C. Am J Gastroenterology 1995: 90: 1246-1249.
24. De SalvoGL, Noventa F, Chemello L, Pontisso P, Alberti A. Variables that influence response to different interferon schedules in chronic hepatitis C and predictive models. J Viral Hepat 1997: 4(SuppI 1): 79-83.
25. Ascione A, De Luca M, Canestini C, Di Costanzo GO, Raimondo G, Longo G et al. Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study. Ital J Gastroenterol Hepatol 1998: 30: 517-23.
26. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M et al. Side effects of high-dose interferon therapy for chronic hepatitis. J Hepatol 1996: 25: 283-291.
27. Wang X, Sherker AH. In vitro effects of interferon alpha-2b on hepatitis C virus replication in lymphocytes (abstract). Hepatology 1995: 22: 333A.
28. Davis GL, Lindsay K, Albrecht J et al: Predictors of response to recombinant alpha interferon treatment in patients with chronic hepatitis C. Hepatology 1990: 12: 905.
29. Marcellin P, Pouteau M, Martinot-Peignoux M et al. Lack of benefit of escalating dosage of interferon alpha in patients with chronic hepatitis C. Gastroenterology 1995: 109: 156.
30. Fong TL, Morgan TR, Phan CG, Hoefs JC. Raising the dose of interferon does not improve the response in chronic hepatitis C. J Clin Gastroenterol 1995: 20: 42-14.
31. Ferenci P, Stauber R, Propst A, Fiedler R, Muller C, Gschwantler M et al. Dose increase augments response rate to interferon-alpha in chronic hepatitis C. Dig Dis Sei 1996: 41(Suppl 12): S103108.
32. Sherman KE, Sickler J, Weber FL, Thee D. HCV treatment of interferon non-responders with monthly HCV titer based interferon dose-escalation: a randomized pilot trial. Hepatology 1998: 28: 283A.
33. Nakamura H, Ito H, Kimura Y, Takeda A, Ogawa H, Kanazawa S et al. The importance of initial daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: a multicenter randomized trial. Hepatogastroenterology 1998: 45: 1045-1055.
34. Nomura H, Kimura Y, Tada H, Hisano C, Morita C, Okamoto O et al. Effective administration methods and dosages of interferon therapy for chronic hepatitis C. Clin Ther 1996: 18: 671-679.
35. Farrell G, Cooksley WG, Dudley FJ, Watson K. Efficacy and tolerance of a 6-month course of daily interferon alpha 2a for chronic hepatitis C with cirrhosis. J Viral Hepat 1997: 4: 317323.
36. Kuboki M, Shimabara M, Mitsui Y, Iguchi Y, Ohno S, Kunieda T et al. A novel interferon alpha treatment as a continuous intravenous infusion in patients with high viremic hepatitis C genotype Ib (abstract). Hepatology 1998: 28: 376A.
37. Pettit DK, Bonnert TP, Eisenman J et al. Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling. J Biol Chem 1997: 272: 2312-2318.
38. Cooreman MP, Sentjens R, Weegink C, Cuypers T, Reesink HW. Efficacy of two-week, three times daily high dose interferon-alpha treatment for chronic hepatitis C virus disease (abstract). Hepatology 1998: 28: 284A.
39. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelsen AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997: 26: 226231.
40. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layd- en TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998: 282: 103-107.
41. Bresters D, Mauser-Bunschoten EP, Cuypers HT et al. Disappearance of hepatitis C virus RNA in plasma during interferon alpha-2b treatment in hemophilia patients. Scand J Gastroenterology 1992: 27: 166.
42. Stewart ÇA, Hofmann CM, Luketic AJ, Sanyal AJ, Sterling RK, Shiffman ML. A randomized controlled trial or daily versus threee times weekly interferon alpha-2a in patients with chronic HCV and either elevated or persistently normal ALT (abstract). Gastroenterology 1998: 114: 1345.
43. Gonzalez HJ, Ho SB, Gross JB, Peine C, McKee D, Smith T. High dose induction therapy with alpha interferon is effective in patients with high hepatitis C viral load (abstract). Gastroenterology 1998: 114: A1247.
44. Ouzan D, Babany G, Valla D, Opolon P. Comparison of high initial and fixed-dose regimens of interferon alpha-2a in chronic hepatitis C: a randomized controlled trial. J Viral Hepat 1998: 5: 53-59.
45. Freilich BL, Eisenback JB, Raines J, Jackson L, Van Ommeren T, Cornish K. Sustained response rates of chronic hepatitis C patients treated with interferon alpha with doses tailored to pretreatment HCV RNA levels: a prospective randomized pilot study (abstract). Gastroenterology 1998: 114: A1242.
46. Perez R, Pravia R, Artimez ML, Linares A, Lombrana JL, PerezLopez R et al. A comparison between two induction regimes for the interferon treatment of chronic hepatitis C: Response related factors. Rev Esp Enferm Dig 1997: 89: 159-173.